A phase 1b randomised double-blinded placebo-controlled study of a Bundibugyo virus disease vaccine, ChAdOx1 Ebola BDBV Vaccine (Recombinant), in healthy participants aged 18 – 55 years in Uganda.

INTERVENTION: ChAdOx1 Ebola BDBV Vaccine sodium chloride CONDITION: ; Ebola Ebola PRIMARY OUTCOME: Occurrence of solicited local and systemic reactogenicity signs and symptoms for 7 days following vaccination. ; Occurrence of unsolicited adverse events (AEs) for 28 days following vaccination.; Occurrence of abnormal safety laboratory measures for duration of the study period. Occurrence of serious adverse events (SAEs) and adverse events of special interest (AESIs) for duration of the study period.; SECONDARY OUTCOME: Assessment of immunogenicity response after one dose immunisation through ; a) BDBV‐specific IgG enyme‐linked immunosorbent assay (ELISA) and/or ; b) BDBV‐specific interferon gamma T cell enzyme‐linked immunospot assay (ELISpot) ; INCLUSION CRITERIA: Adults aged between 18 to 55 years (inclusive) at the time of screening. Medically healthy, such that according to investigator judgement, hospitalisation within the study period is not anticipated, and the participant appears likely to be able to remain a study participant through the end of protocol‐specified follow‐up. Planned elective procedures for pre‐existing conditions are allowable. Able to attend the scheduled visits and to comply with all study procedures. Willing and able to give informed consent for participation in the study. Able to provide a reliable past medical history confirmed where necessary, at the investigator’s discretion, by the participant’s usual health care provider. Willing to allow usual health care provider, if appropriate, to be notified of participation in the study. Agreement to refrain from planned blood donation during the study (see also section 8.6). For participants of childbearing potential